A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
Status:
Terminated
Trial end date:
2021-04-30
Target enrollment:
Participant gender:
Summary
This is a placebo-controlled, randomized, double-blind study to evaluate the
pharmacokinetics, safety and antiviral activity of galidesivir in subjects with yellow fever
(YF) or COVID-19.
Phase:
Phase 1
Details
Lead Sponsor:
BioCryst Pharmaceuticals
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)